Retatrutide Dosage Chart

Retatrutide (LY3437943) is a synthetic peptide from Eli Lilly that simultaneously activates GIP, GLP-1, and glucagon receptors. A fatty diacid conjugation extends its half-life to ~6 days, enabling once-weekly subcutaneous dosing. The Phase 2 protocol escalates 2 → 4 → 8 → 12 mg in four-week steps; Phase 3 TRIUMPH-4 used a 12 mg maintenance dose.

Not yet FDA-approved. NDA expected Q4 2026–Q1 2027 with a PDUFA target in mid-to-late 2027.